Loading…
Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis
To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A). Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included. 14-day mortality...
Saved in:
Published in: | Indian journal of pharmacology 2015-01, Vol.47 (1), p.95-100 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c595t-c7927977bdd61f48ab39c627ef17de89589ac2fbb8551742454b7d310648e6173 |
---|---|
cites | cdi_FETCH-LOGICAL-c595t-c7927977bdd61f48ab39c627ef17de89589ac2fbb8551742454b7d310648e6173 |
container_end_page | 100 |
container_issue | 1 |
container_start_page | 95 |
container_title | Indian journal of pharmacology |
container_volume | 47 |
creator | Balkan, Ilker Inanc Batirel, Ayse Karabay, Oguz Agalar, Canan Akalin, Serife Alici, Ozlem Alp, Emine Altay, Fatma Aybala Altin, Nilgun Arslan, Ferhat Aslan, Turan Bekiroglu, Nural Cesur, Salih Celik, Aygul Dogan Dogan, Mustafa Durdu, Bulent Duygu, Fazilet Engin, Aynur Engin, Derya Ozturk Gonen, Ibak Guclu, Ertugrul Guven, Tumer Hatipoglu, Cigdem Ataman Hosoglu, Salih Karahocagil, Mustafa Kasim Kilic, Aysegul Ulu Ormen, Bahar Ozdemir, Davut Ozer, Serdar Oztoprak, Nefise Sezak, Nurbanu Turhan, Vedat Turker, Nesrin Yilmaz, Hava |
description | To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A).
Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included.
14-day mortality.
Microbial eradication and clinical improvement.
Thirty-six patients in the COL monotherapy (CM) group and 71 in the non-COL based combinations (NCC) group were included in the study. Mean age was 59.98 ± 20 years (range: 18-89) and 50.5% were male. Median duration of follow-up was 40 days (range: 9-297). The 14-day survival rates were 52.8% in CM and 47.23% in NCC group (P = 0.36). Microbiological eradication was achieved in 69% of CM and 83% of NCC group (P = 0.13). Treatment failure was detected in 22.9% of cases in both CM and NCC groups. Univariate analysis revealed that mean age (P = 0.001), Charlson comorbidity index (P = 0.03), duration of hospital stay before MDR-A BSI (P = 0.04), Pitt bacteremia score (P = 0.043) and Acute Physiology and Chronic Health Evaluation II score (P = 0.05) were significant in terms of 14-day mortality. Advanced age (P = 0.01) and duration of hospital stay before MDR-A BSI (P = 0.04) were independently associated with 14-day mortality in multivariate analysis.
No significant difference was detected between CM and non-COL based combinations in the treatment of MDR-A BSIs in terms of efficacy and 14-day mortality. |
doi_str_mv | 10.4103/0253-7613.150383 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4375827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A400188445</galeid><sourcerecordid>A400188445</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-c7927977bdd61f48ab39c627ef17de89589ac2fbb8551742454b7d310648e6173</originalsourceid><addsrcrecordid>eNptkk-P1CAYxonRuOPq3ZMh8dwRChTqwWQy8V-yiRc9E0rpLJsWKtBN5qP57XzrrKObTDgQeJ_nB7w8CL2mZMspYe9ILVglG8q2VBCm2BO0oW2rKiYFfYo25_IVepHzHYE1b5vn6KoWqqaMthv0ax-n2SSfY8BxwDaOPhcf8BRDLLcumfmITehxiKE6F22cOh9M8TFkDGsQ4pKcKZMLZcVMy1h81aflgJPLYDKwv7M-uBI7Y4tLOM_zFndjjH1erRNwBmf_IN9jcyJYwIE0uZJintfqvYPbmPEIzJfo2WDG7F49zNfox6eP3_dfqptvn7_udzeVFa0olZVtLVspu75v6MCV6Vhrm1q6gcreqVao1th66DolBJW85oJ3smeUNFy5hkp2jT6cuPPSTa5f75TMqOfkJ5OOOhqvH1eCv9WHeK85_IKqV8DbB0CKPxeXi76LS4JXZE0bISSBY8k_1cGMTkMzIsDs5LPVO04IVYpzAarqgurgAvzUGIMbPGw_0m8v6GH0bvL2ooGcDBZanpMbzg-lRK-Z02uo9BoqfcocWN7836Cz4W_I2G8It9YH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1655701740</pqid></control><display><type>article</type><title>Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Balkan, Ilker Inanc ; Batirel, Ayse ; Karabay, Oguz ; Agalar, Canan ; Akalin, Serife ; Alici, Ozlem ; Alp, Emine ; Altay, Fatma Aybala ; Altin, Nilgun ; Arslan, Ferhat ; Aslan, Turan ; Bekiroglu, Nural ; Cesur, Salih ; Celik, Aygul Dogan ; Dogan, Mustafa ; Durdu, Bulent ; Duygu, Fazilet ; Engin, Aynur ; Engin, Derya Ozturk ; Gonen, Ibak ; Guclu, Ertugrul ; Guven, Tumer ; Hatipoglu, Cigdem Ataman ; Hosoglu, Salih ; Karahocagil, Mustafa Kasim ; Kilic, Aysegul Ulu ; Ormen, Bahar ; Ozdemir, Davut ; Ozer, Serdar ; Oztoprak, Nefise ; Sezak, Nurbanu ; Turhan, Vedat ; Turker, Nesrin ; Yilmaz, Hava</creator><creatorcontrib>Balkan, Ilker Inanc ; Batirel, Ayse ; Karabay, Oguz ; Agalar, Canan ; Akalin, Serife ; Alici, Ozlem ; Alp, Emine ; Altay, Fatma Aybala ; Altin, Nilgun ; Arslan, Ferhat ; Aslan, Turan ; Bekiroglu, Nural ; Cesur, Salih ; Celik, Aygul Dogan ; Dogan, Mustafa ; Durdu, Bulent ; Duygu, Fazilet ; Engin, Aynur ; Engin, Derya Ozturk ; Gonen, Ibak ; Guclu, Ertugrul ; Guven, Tumer ; Hatipoglu, Cigdem Ataman ; Hosoglu, Salih ; Karahocagil, Mustafa Kasim ; Kilic, Aysegul Ulu ; Ormen, Bahar ; Ozdemir, Davut ; Ozer, Serdar ; Oztoprak, Nefise ; Sezak, Nurbanu ; Turhan, Vedat ; Turker, Nesrin ; Yilmaz, Hava</creatorcontrib><description>To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A).
Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included.
14-day mortality.
Microbial eradication and clinical improvement.
Thirty-six patients in the COL monotherapy (CM) group and 71 in the non-COL based combinations (NCC) group were included in the study. Mean age was 59.98 ± 20 years (range: 18-89) and 50.5% were male. Median duration of follow-up was 40 days (range: 9-297). The 14-day survival rates were 52.8% in CM and 47.23% in NCC group (P = 0.36). Microbiological eradication was achieved in 69% of CM and 83% of NCC group (P = 0.13). Treatment failure was detected in 22.9% of cases in both CM and NCC groups. Univariate analysis revealed that mean age (P = 0.001), Charlson comorbidity index (P = 0.03), duration of hospital stay before MDR-A BSI (P = 0.04), Pitt bacteremia score (P = 0.043) and Acute Physiology and Chronic Health Evaluation II score (P = 0.05) were significant in terms of 14-day mortality. Advanced age (P = 0.01) and duration of hospital stay before MDR-A BSI (P = 0.04) were independently associated with 14-day mortality in multivariate analysis.
No significant difference was detected between CM and non-COL based combinations in the treatment of MDR-A BSIs in terms of efficacy and 14-day mortality.</description><identifier>ISSN: 0253-7613</identifier><identifier>EISSN: 1998-3751</identifier><identifier>DOI: 10.4103/0253-7613.150383</identifier><identifier>PMID: 25821319</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Acinetobacter ; Acinetobacter - drug effects ; Acinetobacter - pathogenicity ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - microbiology ; Acinetobacter Infections - mortality ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; APACHE ; Bacteremia - drug therapy ; Bacteremia - microbiology ; Bacteremia - mortality ; Bacterial infections ; Blood ; Chi-Square Distribution ; Colistin - adverse effects ; Colistin - therapeutic use ; Combination drug therapy ; Comorbidity ; Comparative analysis ; Comparative studies ; Drug resistance ; Drug Resistance, Multiple, Bacterial ; Drug Therapy, Combination ; Female ; Health aspects ; Host-parasite relationships ; Humans ; Kaplan-Meier Estimate ; Length of Stay ; Male ; Middle Aged ; Multivariate Analysis ; Pharmacology ; Prevention ; Proportional Hazards Models ; Remission Induction ; Retrospective Studies ; Risk Factors ; Tertiary Care Centers ; Time Factors ; Treatment Outcome ; Turkey ; Young Adult</subject><ispartof>Indian journal of pharmacology, 2015-01, Vol.47 (1), p.95-100</ispartof><rights>COPYRIGHT 2015 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt Ltd Feb 2015</rights><rights>Copyright: © Indian Journal of Pharmacology 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-c7927977bdd61f48ab39c627ef17de89589ac2fbb8551742454b7d310648e6173</citedby><cites>FETCH-LOGICAL-c595t-c7927977bdd61f48ab39c627ef17de89589ac2fbb8551742454b7d310648e6173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375827/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1655701740?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,44589,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25821319$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balkan, Ilker Inanc</creatorcontrib><creatorcontrib>Batirel, Ayse</creatorcontrib><creatorcontrib>Karabay, Oguz</creatorcontrib><creatorcontrib>Agalar, Canan</creatorcontrib><creatorcontrib>Akalin, Serife</creatorcontrib><creatorcontrib>Alici, Ozlem</creatorcontrib><creatorcontrib>Alp, Emine</creatorcontrib><creatorcontrib>Altay, Fatma Aybala</creatorcontrib><creatorcontrib>Altin, Nilgun</creatorcontrib><creatorcontrib>Arslan, Ferhat</creatorcontrib><creatorcontrib>Aslan, Turan</creatorcontrib><creatorcontrib>Bekiroglu, Nural</creatorcontrib><creatorcontrib>Cesur, Salih</creatorcontrib><creatorcontrib>Celik, Aygul Dogan</creatorcontrib><creatorcontrib>Dogan, Mustafa</creatorcontrib><creatorcontrib>Durdu, Bulent</creatorcontrib><creatorcontrib>Duygu, Fazilet</creatorcontrib><creatorcontrib>Engin, Aynur</creatorcontrib><creatorcontrib>Engin, Derya Ozturk</creatorcontrib><creatorcontrib>Gonen, Ibak</creatorcontrib><creatorcontrib>Guclu, Ertugrul</creatorcontrib><creatorcontrib>Guven, Tumer</creatorcontrib><creatorcontrib>Hatipoglu, Cigdem Ataman</creatorcontrib><creatorcontrib>Hosoglu, Salih</creatorcontrib><creatorcontrib>Karahocagil, Mustafa Kasim</creatorcontrib><creatorcontrib>Kilic, Aysegul Ulu</creatorcontrib><creatorcontrib>Ormen, Bahar</creatorcontrib><creatorcontrib>Ozdemir, Davut</creatorcontrib><creatorcontrib>Ozer, Serdar</creatorcontrib><creatorcontrib>Oztoprak, Nefise</creatorcontrib><creatorcontrib>Sezak, Nurbanu</creatorcontrib><creatorcontrib>Turhan, Vedat</creatorcontrib><creatorcontrib>Turker, Nesrin</creatorcontrib><creatorcontrib>Yilmaz, Hava</creatorcontrib><title>Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis</title><title>Indian journal of pharmacology</title><addtitle>Indian J Pharmacol</addtitle><description>To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A).
Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included.
14-day mortality.
Microbial eradication and clinical improvement.
Thirty-six patients in the COL monotherapy (CM) group and 71 in the non-COL based combinations (NCC) group were included in the study. Mean age was 59.98 ± 20 years (range: 18-89) and 50.5% were male. Median duration of follow-up was 40 days (range: 9-297). The 14-day survival rates were 52.8% in CM and 47.23% in NCC group (P = 0.36). Microbiological eradication was achieved in 69% of CM and 83% of NCC group (P = 0.13). Treatment failure was detected in 22.9% of cases in both CM and NCC groups. Univariate analysis revealed that mean age (P = 0.001), Charlson comorbidity index (P = 0.03), duration of hospital stay before MDR-A BSI (P = 0.04), Pitt bacteremia score (P = 0.043) and Acute Physiology and Chronic Health Evaluation II score (P = 0.05) were significant in terms of 14-day mortality. Advanced age (P = 0.01) and duration of hospital stay before MDR-A BSI (P = 0.04) were independently associated with 14-day mortality in multivariate analysis.
No significant difference was detected between CM and non-COL based combinations in the treatment of MDR-A BSIs in terms of efficacy and 14-day mortality.</description><subject>Acinetobacter</subject><subject>Acinetobacter - drug effects</subject><subject>Acinetobacter - pathogenicity</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Acinetobacter Infections - microbiology</subject><subject>Acinetobacter Infections - mortality</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>APACHE</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - microbiology</subject><subject>Bacteremia - mortality</subject><subject>Bacterial infections</subject><subject>Blood</subject><subject>Chi-Square Distribution</subject><subject>Colistin - adverse effects</subject><subject>Colistin - therapeutic use</subject><subject>Combination drug therapy</subject><subject>Comorbidity</subject><subject>Comparative analysis</subject><subject>Comparative studies</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Health aspects</subject><subject>Host-parasite relationships</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pharmacology</subject><subject>Prevention</subject><subject>Proportional Hazards Models</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Tertiary Care Centers</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Turkey</subject><subject>Young Adult</subject><issn>0253-7613</issn><issn>1998-3751</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkk-P1CAYxonRuOPq3ZMh8dwRChTqwWQy8V-yiRc9E0rpLJsWKtBN5qP57XzrrKObTDgQeJ_nB7w8CL2mZMspYe9ILVglG8q2VBCm2BO0oW2rKiYFfYo25_IVepHzHYE1b5vn6KoWqqaMthv0ax-n2SSfY8BxwDaOPhcf8BRDLLcumfmITehxiKE6F22cOh9M8TFkDGsQ4pKcKZMLZcVMy1h81aflgJPLYDKwv7M-uBI7Y4tLOM_zFndjjH1erRNwBmf_IN9jcyJYwIE0uZJintfqvYPbmPEIzJfo2WDG7F49zNfox6eP3_dfqptvn7_udzeVFa0olZVtLVspu75v6MCV6Vhrm1q6gcreqVao1th66DolBJW85oJ3smeUNFy5hkp2jT6cuPPSTa5f75TMqOfkJ5OOOhqvH1eCv9WHeK85_IKqV8DbB0CKPxeXi76LS4JXZE0bISSBY8k_1cGMTkMzIsDs5LPVO04IVYpzAarqgurgAvzUGIMbPGw_0m8v6GH0bvL2ooGcDBZanpMbzg-lRK-Z02uo9BoqfcocWN7836Cz4W_I2G8It9YH</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Balkan, Ilker Inanc</creator><creator>Batirel, Ayse</creator><creator>Karabay, Oguz</creator><creator>Agalar, Canan</creator><creator>Akalin, Serife</creator><creator>Alici, Ozlem</creator><creator>Alp, Emine</creator><creator>Altay, Fatma Aybala</creator><creator>Altin, Nilgun</creator><creator>Arslan, Ferhat</creator><creator>Aslan, Turan</creator><creator>Bekiroglu, Nural</creator><creator>Cesur, Salih</creator><creator>Celik, Aygul Dogan</creator><creator>Dogan, Mustafa</creator><creator>Durdu, Bulent</creator><creator>Duygu, Fazilet</creator><creator>Engin, Aynur</creator><creator>Engin, Derya Ozturk</creator><creator>Gonen, Ibak</creator><creator>Guclu, Ertugrul</creator><creator>Guven, Tumer</creator><creator>Hatipoglu, Cigdem Ataman</creator><creator>Hosoglu, Salih</creator><creator>Karahocagil, Mustafa Kasim</creator><creator>Kilic, Aysegul Ulu</creator><creator>Ormen, Bahar</creator><creator>Ozdemir, Davut</creator><creator>Ozer, Serdar</creator><creator>Oztoprak, Nefise</creator><creator>Sezak, Nurbanu</creator><creator>Turhan, Vedat</creator><creator>Turker, Nesrin</creator><creator>Yilmaz, Hava</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis</title><author>Balkan, Ilker Inanc ; Batirel, Ayse ; Karabay, Oguz ; Agalar, Canan ; Akalin, Serife ; Alici, Ozlem ; Alp, Emine ; Altay, Fatma Aybala ; Altin, Nilgun ; Arslan, Ferhat ; Aslan, Turan ; Bekiroglu, Nural ; Cesur, Salih ; Celik, Aygul Dogan ; Dogan, Mustafa ; Durdu, Bulent ; Duygu, Fazilet ; Engin, Aynur ; Engin, Derya Ozturk ; Gonen, Ibak ; Guclu, Ertugrul ; Guven, Tumer ; Hatipoglu, Cigdem Ataman ; Hosoglu, Salih ; Karahocagil, Mustafa Kasim ; Kilic, Aysegul Ulu ; Ormen, Bahar ; Ozdemir, Davut ; Ozer, Serdar ; Oztoprak, Nefise ; Sezak, Nurbanu ; Turhan, Vedat ; Turker, Nesrin ; Yilmaz, Hava</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-c7927977bdd61f48ab39c627ef17de89589ac2fbb8551742454b7d310648e6173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acinetobacter</topic><topic>Acinetobacter - drug effects</topic><topic>Acinetobacter - pathogenicity</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Acinetobacter Infections - microbiology</topic><topic>Acinetobacter Infections - mortality</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>APACHE</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - microbiology</topic><topic>Bacteremia - mortality</topic><topic>Bacterial infections</topic><topic>Blood</topic><topic>Chi-Square Distribution</topic><topic>Colistin - adverse effects</topic><topic>Colistin - therapeutic use</topic><topic>Combination drug therapy</topic><topic>Comorbidity</topic><topic>Comparative analysis</topic><topic>Comparative studies</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Health aspects</topic><topic>Host-parasite relationships</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pharmacology</topic><topic>Prevention</topic><topic>Proportional Hazards Models</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Tertiary Care Centers</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Turkey</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balkan, Ilker Inanc</creatorcontrib><creatorcontrib>Batirel, Ayse</creatorcontrib><creatorcontrib>Karabay, Oguz</creatorcontrib><creatorcontrib>Agalar, Canan</creatorcontrib><creatorcontrib>Akalin, Serife</creatorcontrib><creatorcontrib>Alici, Ozlem</creatorcontrib><creatorcontrib>Alp, Emine</creatorcontrib><creatorcontrib>Altay, Fatma Aybala</creatorcontrib><creatorcontrib>Altin, Nilgun</creatorcontrib><creatorcontrib>Arslan, Ferhat</creatorcontrib><creatorcontrib>Aslan, Turan</creatorcontrib><creatorcontrib>Bekiroglu, Nural</creatorcontrib><creatorcontrib>Cesur, Salih</creatorcontrib><creatorcontrib>Celik, Aygul Dogan</creatorcontrib><creatorcontrib>Dogan, Mustafa</creatorcontrib><creatorcontrib>Durdu, Bulent</creatorcontrib><creatorcontrib>Duygu, Fazilet</creatorcontrib><creatorcontrib>Engin, Aynur</creatorcontrib><creatorcontrib>Engin, Derya Ozturk</creatorcontrib><creatorcontrib>Gonen, Ibak</creatorcontrib><creatorcontrib>Guclu, Ertugrul</creatorcontrib><creatorcontrib>Guven, Tumer</creatorcontrib><creatorcontrib>Hatipoglu, Cigdem Ataman</creatorcontrib><creatorcontrib>Hosoglu, Salih</creatorcontrib><creatorcontrib>Karahocagil, Mustafa Kasim</creatorcontrib><creatorcontrib>Kilic, Aysegul Ulu</creatorcontrib><creatorcontrib>Ormen, Bahar</creatorcontrib><creatorcontrib>Ozdemir, Davut</creatorcontrib><creatorcontrib>Ozer, Serdar</creatorcontrib><creatorcontrib>Oztoprak, Nefise</creatorcontrib><creatorcontrib>Sezak, Nurbanu</creatorcontrib><creatorcontrib>Turhan, Vedat</creatorcontrib><creatorcontrib>Turker, Nesrin</creatorcontrib><creatorcontrib>Yilmaz, Hava</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balkan, Ilker Inanc</au><au>Batirel, Ayse</au><au>Karabay, Oguz</au><au>Agalar, Canan</au><au>Akalin, Serife</au><au>Alici, Ozlem</au><au>Alp, Emine</au><au>Altay, Fatma Aybala</au><au>Altin, Nilgun</au><au>Arslan, Ferhat</au><au>Aslan, Turan</au><au>Bekiroglu, Nural</au><au>Cesur, Salih</au><au>Celik, Aygul Dogan</au><au>Dogan, Mustafa</au><au>Durdu, Bulent</au><au>Duygu, Fazilet</au><au>Engin, Aynur</au><au>Engin, Derya Ozturk</au><au>Gonen, Ibak</au><au>Guclu, Ertugrul</au><au>Guven, Tumer</au><au>Hatipoglu, Cigdem Ataman</au><au>Hosoglu, Salih</au><au>Karahocagil, Mustafa Kasim</au><au>Kilic, Aysegul Ulu</au><au>Ormen, Bahar</au><au>Ozdemir, Davut</au><au>Ozer, Serdar</au><au>Oztoprak, Nefise</au><au>Sezak, Nurbanu</au><au>Turhan, Vedat</au><au>Turker, Nesrin</au><au>Yilmaz, Hava</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis</atitle><jtitle>Indian journal of pharmacology</jtitle><addtitle>Indian J Pharmacol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>47</volume><issue>1</issue><spage>95</spage><epage>100</epage><pages>95-100</pages><issn>0253-7613</issn><eissn>1998-3751</eissn><abstract>To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A).
Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included.
14-day mortality.
Microbial eradication and clinical improvement.
Thirty-six patients in the COL monotherapy (CM) group and 71 in the non-COL based combinations (NCC) group were included in the study. Mean age was 59.98 ± 20 years (range: 18-89) and 50.5% were male. Median duration of follow-up was 40 days (range: 9-297). The 14-day survival rates were 52.8% in CM and 47.23% in NCC group (P = 0.36). Microbiological eradication was achieved in 69% of CM and 83% of NCC group (P = 0.13). Treatment failure was detected in 22.9% of cases in both CM and NCC groups. Univariate analysis revealed that mean age (P = 0.001), Charlson comorbidity index (P = 0.03), duration of hospital stay before MDR-A BSI (P = 0.04), Pitt bacteremia score (P = 0.043) and Acute Physiology and Chronic Health Evaluation II score (P = 0.05) were significant in terms of 14-day mortality. Advanced age (P = 0.01) and duration of hospital stay before MDR-A BSI (P = 0.04) were independently associated with 14-day mortality in multivariate analysis.
No significant difference was detected between CM and non-COL based combinations in the treatment of MDR-A BSIs in terms of efficacy and 14-day mortality.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>25821319</pmid><doi>10.4103/0253-7613.150383</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0253-7613 |
ispartof | Indian journal of pharmacology, 2015-01, Vol.47 (1), p.95-100 |
issn | 0253-7613 1998-3751 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4375827 |
source | Publicly Available Content (ProQuest); PubMed Central |
subjects | Acinetobacter Acinetobacter - drug effects Acinetobacter - pathogenicity Acinetobacter Infections - drug therapy Acinetobacter Infections - microbiology Acinetobacter Infections - mortality Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibiotics APACHE Bacteremia - drug therapy Bacteremia - microbiology Bacteremia - mortality Bacterial infections Blood Chi-Square Distribution Colistin - adverse effects Colistin - therapeutic use Combination drug therapy Comorbidity Comparative analysis Comparative studies Drug resistance Drug Resistance, Multiple, Bacterial Drug Therapy, Combination Female Health aspects Host-parasite relationships Humans Kaplan-Meier Estimate Length of Stay Male Middle Aged Multivariate Analysis Pharmacology Prevention Proportional Hazards Models Remission Induction Retrospective Studies Risk Factors Tertiary Care Centers Time Factors Treatment Outcome Turkey Young Adult |
title | Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T08%3A40%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20colistin%20monotherapy%20and%20non-colistin%20combinations%20in%20the%20treatment%20of%20multi-drug%20resistant%20Acinetobacter%20spp.%20bloodstream%20infections:%20a%20multicenter%20retrospective%20analysis&rft.jtitle=Indian%20journal%20of%20pharmacology&rft.au=Balkan,%20Ilker%20Inanc&rft.date=2015-01-01&rft.volume=47&rft.issue=1&rft.spage=95&rft.epage=100&rft.pages=95-100&rft.issn=0253-7613&rft.eissn=1998-3751&rft_id=info:doi/10.4103/0253-7613.150383&rft_dat=%3Cgale_pubme%3EA400188445%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c595t-c7927977bdd61f48ab39c627ef17de89589ac2fbb8551742454b7d310648e6173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1655701740&rft_id=info:pmid/25821319&rft_galeid=A400188445&rfr_iscdi=true |